<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02841215</url>
  </required_header>
  <id_info>
    <org_study_id>P140939</org_study_id>
    <nct_id>NCT02841215</nct_id>
  </id_info>
  <brief_title>Efficacy Study Between Two Different Dosages of an Antiparasitic in Patients With Crusted Scabies</brief_title>
  <acronym>GALECRUSTED</acronym>
  <official_title>A Randomized Controlled Double-blind Trial Assessing the Efficacy of a 400 ug/kg Ivermectin Regime in Patients With Crusted Scabies as Compared to a 200 ug/kg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe forms of scabies (crusted scabies and profuse scabies) require a specific treatment.
      Ivermectin is a recommended treatment in common forms of scabies and represents a promising
      treatment in crusted scabies in case reports. However, response to ivermectin remains
      variable among studies, and there is no consensus on the schemes to adopt (dosages and
      administrations). Ivermectin at 400 µg/kg has already been used, without showing toxicity (in
      head lice treatment in particular). Investigators propose to demonstrate that 400µg/kg
      ivermectin dosage will show better efficacy than a 200µg/kg in patients with severe forms of
      scabies (crusted and profuse).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2017</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of a successful treatment defined by : -Two negative parasitologic or two dermoscopic exams</measure>
    <time_frame>Days 21+/-2 days</time_frame>
    <description>Parasitologic or dermoscopic exams will be perform at days 18 +/-2days and at days 21+/-2 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of a successful treatment defined by : - A clinical response : disappearance of clinical active lesions</measure>
    <time_frame>Days 28+/- 2 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse effects</measure>
    <time_frame>Days 18 +/-2 days, Days 21+/-2 days and Days 28+/-2 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Gale</condition>
  <condition>Severe Forms of Scabies</condition>
  <condition>Oral Parasitic Drug</condition>
  <condition>Ivermectin</condition>
  <arm_group>
    <arm_group_label>Oral ivermectin 400 µg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral ivermectin 400 µg/kg + topical treatment (permethrin 5% cream) + emollient cream (Dexeryl® or other)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral ivermectin 200 µg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral ivermectin 200 µg/kg + topical treatment (permethrin 5% cream) + emollient cream (Dexeryl® or other)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin 200 µg/kg</intervention_name>
    <description>Oral ivermectin 200 µg/kg three times (D0, D7 and D14) + topical treatment (permethrin 5% cream) on skin, hair and genital organs (D0 and D7) + emollient cream (Dexeryl® or other) daily on skin (D0 to D28)</description>
    <arm_group_label>Oral ivermectin 200 µg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin 400 µg/kg</intervention_name>
    <description>Oral ivermectin 400 µg/kg three times (D0, D7 and D14) + topical treatment (permethrin 5% cream) on skin, hair and genital organs (D0 and D7) + emollient cream (Dexeryl® or other)daily on skin (D0 to D28)</description>
    <arm_group_label>Oral ivermectin 400 µg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients ≥ 18 years old, diagnosed with severe forms of scabies

          1. clinical criteria :

               -  crusted scabies: hyperkeratosis dermatosis of the hands, feet and

               -  profuse scabies : erythematous scaly eruption of the neck, face and trunk

          2. paraclinical criteria:

               -  Positive parasitological test with &gt; 10 mites per exam

               -  or dermoscopic exam with signs of scabies Consent from patient or his/her legal
                  representant, trustworthy person or family member

        Exclusion Criteria:

          -  Pregnant or breastfeeding women

          -  Intolerance to ivermectin or topical treatment (permethrin 5% cream) or emollient
             cream

          -  Use of anti parasitological drug (ivermectin or albendazole) within the past 7 days

          -  Participation in other biomedical drug research
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giao DO-PHAM, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giao DO-PHAM, MD</last_name>
    <phone>(0)1 49 81 45 09</phone>
    <phone_ext>+33</phone_ext>
    <email>giao.do-pham@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Henri Mondor Hospital</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laetitia Gregoire, M.Sc</last_name>
      <phone>(0) 1 49 81 41 64</phone>
      <phone_ext>+33</phone_ext>
      <email>laetitia.gregoire@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/24069468</url>
  </link>
  <link>
    <url>http://www.cdc.gov/parasites/scabies/health_professionals/meds.html</url>
  </link>
  <link>
    <url>http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000320.pub2/full</url>
  </link>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2016</study_first_submitted>
  <study_first_submitted_qc>July 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2016</study_first_posted>
  <last_update_submitted>December 7, 2016</last_update_submitted>
  <last_update_submitted_qc>December 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gale</keyword>
  <keyword>Severe forms of scabies</keyword>
  <keyword>Oral parasitic drug</keyword>
  <keyword>Ivermectin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scabies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
    <mesh_term>Emollients</mesh_term>
    <mesh_term>Permethrin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

